Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2010 Apr 21

PMID 20405179

Citations 12

Authors

Brian ONuallain

Angela D Williams

Helen P McWilliams-Koeppen

Luis Acero

Alfred Weber

Hartmut Ehrlich

Hans P Schwarz

Alan Solomon

Affiliations

Soon will be listed here.

Abstract

Introduction: We have previously shown that a subpopulation of naturally occurring human IgGs has therapeutic potential for the amyloid-associated disorders. These molecules cross-react with conformational epitopes on amyloidogenic assemblies, including amyloid beta (Abeta) protein fibrils that are a pathological hallmark of Alzheimer's disease.

Materials And Methods: Using our europium-linked immunosorbant assay, we established that approximately 95% of 260 screened donor plasma samples had amyloid fibril-reactive IgGs and Abeta conformer-reactive IgGs with minimal binding to Abeta monomers. Anti-amyloidogenic reactivity was diverse and attributed to Abeta targeting multiple fibril-related binding sites and/or variations in multidentate binding.

Results And Discussion: There was no correlation between anti-fibril and anti-oligomer reactivity and donor age (19 to 60 years old) or gender. These findings demonstrate the inherent but diverse anti-amyloidogenic activity of natural IgGs contained in normal plasma.

Conclusion: Our studies provide support for investigating the clinical significance and physiological function of this novel class of antibodies.

Citing Articles

Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine.

Marciani D Research (Wash D C). 2019; 2019:5341375.

PMID: 31549066 PMC: 6750119. DOI: 10.34133/2019/5341375.

Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches.

Hussain R, Zubair H, Pursell S, Shahab M Brain Sci. 2018; 8(9).

PMID: 30223579 PMC: 6162719. DOI: 10.3390/brainsci8090177.

Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo.

Cattepoel S, Gaida A, Kropf A, Nolte M, Bolli R, Miescher S PLoS One. 2016; 11(8):e0161826.

PMID: 27561008 PMC: 4999199. DOI: 10.1371/journal.pone.0161826.

IgG Conformer's Binding to Amyloidogenic Aggregates.

Phay M, Welzel A, Williams A, McWilliams-Koeppen H, Blinder V, OMalley T PLoS One. 2015; 10(9):e0137344.

PMID: 26367058 PMC: 4569075. DOI: 10.1371/journal.pone.0137344.

Alpha-synuclein levels in blood plasma decline with healthy aging.

Koehler N, Stransky E, Meyer M, Gaertner S, Shing M, Schnaidt M PLoS One. 2015; 10(4):e0123444.

PMID: 25844871 PMC: 4386828. DOI: 10.1371/journal.pone.0123444.

References

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Istrin G, Bosis E, Solomon B . Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res. 2006; 84(2):434-43. DOI: 10.1002/jnr.20886. View

Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A . Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett. 2004; 355(3):226-30. DOI: 10.1016/j.neulet.2003.10.071. View

Stefani M . Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta. 2004; 1739(1):5-25. DOI: 10.1016/j.bbadis.2004.08.004. View

ONuallain B, Hrncic R, Wall J, Weiss D, Solomon A . Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol. 2006; 176(11):7071-8. DOI: 10.4049/jimmunol.176.11.7071. View

Mruthinti S, Buccafusco J, Hill W, Waller J, Jackson T, Zamrini E . Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004; 25(8):1023-32. DOI: 10.1016/j.neurobiolaging.2003.11.001. View

Walsh D, Selkoe D . A beta oligomers - a decade of discovery. J Neurochem. 2007; 101(5):1172-84. DOI: 10.1111/j.1471-4159.2006.04426.x. View

ONuallain B, Acero L, Williams A, Koeppen H, Weber A, Schwarz H . Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry. 2008; 47(47):12254-6. DOI: 10.1021/bi801767k. View

Solomon B . Alzheimer's disease and immunotherapy. Curr Alzheimer Res. 2005; 1(3):149-63. DOI: 10.2174/1567205043332126. View

10.

Klyubin I, Betts V, Welzel A, Blennow K, Zetterberg H, Wallin A . Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008; 28(16):4231-7. PMC: 2685151. DOI: 10.1523/JNEUROSCI.5161-07.2008. View

11.

Kuo Y, Emmerling M, Lampert H, Hempelman S, Kokjohn T, Woods A . High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 1999; 257(3):787-91. DOI: 10.1006/bbrc.1999.0552. View

12.

Dodel R, Du Y, Depboylu C, Hampel H, Frolich L, Haag A . Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004; 75(10):1472-4. PMC: 1738770. DOI: 10.1136/jnnp.2003.033399. View

13.

Relkin N, Szabo P, Adamiak B, Burgut T, Monthe C, Lent R . 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008; 30(11):1728-36. DOI: 10.1016/j.neurobiolaging.2007.12.021. View

14.

Solomon A, Weiss D, Wall J . Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2004; 18(6):853-60. DOI: 10.1089/108497803322702824. View

15.

Li Q, Gordon M, Cao C, Ugen K, Morgan D . Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 2007; 8:22. PMC: 1845169. DOI: 10.1186/1471-2202-8-22. View

16.

Falk R, Skinner M . The systemic amyloidoses: an overview. Adv Intern Med. 2000; 45:107-37. View

17.

Moir R, Tseitlin K, Soscia S, Hyman B, Irizarry M, Tanzi R . Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem. 2005; 280(17):17458-63. DOI: 10.1074/jbc.M414176200. View

18.

Haass C, Schlossmacher M, Hung A, Mellon A, Ostaszewski B, Lieberburg I . Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992; 359(6393):322-5. DOI: 10.1038/359322a0. View

19.

Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y . Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res. 2008; 1219:169-79. DOI: 10.1016/j.brainres.2008.02.060. View

20.

Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F . Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain. 2003; 126(Pt 9):1935-9. DOI: 10.1093/brain/awg191. View